Collegium Pharmaceutical Raises Guidance - Stock Soars to All-Time High!
Reading Time: 1 minute
Collegium Pharmaceutical focuses on the development and marketing of drugs for pain management. The product portfolio includes several products, among them Xtampza ER, for oral use, which has been patent-protected since September last year until 2033. Additionally, another revenue driver is Jornay PM, a medication for the treatment of ADHD. In this regard, CEO Vikram Karnani recently pointed to a strong back-to-school season. The market share of Jornay was recently expanded to 23.4% in the USA. The quarterly results presented on November 6 were...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
